1091 results about "Chemo therapy" patented technology

The invention relates to the technical field of medical data processing and prediction, and discloses a chemotherapy adverse reaction prediction and intervention system based on big data. The system integrates an unstructured disease course text and structured inspection data of a patient, generates a time-series symptom event, and performs time window alignment and fusion on the time-series symptom event, a medication record and a physical sign monitoring stream to form a multi-dimensional time-series data block. The system is combined with an external medical knowledge base to construct a dynamic association network among symptoms, medicines and physiological indexes, and dynamically calculates the confidence coefficient of an adverse reaction mode according to real-time data. By using a predictive model of the timing attention mechanism, the system can output a continuous curve of patient risk over time. The system automatically matches and generates a personalized intervention instruction sequence containing specific measures and execution time windows according to key time points and modes when the risk curve exceeds a threshold value. According to the invention, dynamic and advanced early warning and accurate intervention of adverse reaction risks of chemotherapy are realized.

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The invention relates to a double-framework self-developing embolism system based on iodine modified PNIPAM gel and cross-linked albumin microspheres, which simulates a brick wall-concrete effect through a microsphere-gel composite structure and synergistically improves the embolism strength. A novel TACE treatment system is designed and constructed, multiple effects of tracing, embolism, hypoxia enhanced chemotherapy and tumor microenvironment improvement are achieved through the self-developing temperature-sensitive gel-drug carrying microspheres, and the anti-tumor effect is cooperatively improved.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The composition comprises an IGF2BP3 inhibitor and a platinum chemotherapeutic drug. According to the combined medication scheme, the IGF2BP3 function is inhibited to block an ATF4 survival promoting signal channel mediated by the IGF2BP3 function, a synergistic effect is generated with a DNA damage mechanism of platinum drugs, the anti-tumor effect can be remarkably enhanced, chemotherapy drug resistance can be effectively reversed, toxic and side effects are expected to be reduced, and the application prospect is wide. And a new strategy is provided for overcoming the treatment problem of the non-small cell lung cancer, especially platinum-resistant non-small cell lung cancer.

The invention discloses an EGFR (epidermal growth factor receptor) targeted nano-drug carrier and a preparation method thereof, the EGFR targeted nano-drug carrier comprises drug-loading nanoparticles, an erythrocyte membrane coating the drug-loading nanoparticles and GE11 peptide connected to the erythrocyte membrane, and the drug-loading nanoparticles are formed by connecting tannic acid, ellagic acid and 1, 4-phenyldiboronic acid through boric acid ester bonds. The EGFR targeted nano-drug carrier disclosed by the invention can be enriched at an EGFR overexpressed tumor site in a targeted manner, and can be effectively prevented from being cleared by an immune system, and the drug loaded by the drug-loaded nanoparticles is released in a high-active oxygen environment, so that the treatment effect on tumors can be improved, and the toxic and side effects on normal tissues can be reduced; and photothermal therapy and chemotherapy effects can be simultaneously generated under NIR illumination, and the anticancer efficiency can be remarkably improved through the synergistic effect of the photothermal therapy and the chemotherapy.

The invention relates to a double-cavity radiotherapy and chemotherapy integrated treatment capsule for brain glioma, which aims to solve the problems that the existing radioactive seed source or chemotherapy carrier cannot give consideration to radiotherapy and chemotherapy, the dosage is difficult to regulate and control, the medicine distribution is non-uniform and the like. The brain glioma double-cavity radiotherapy and chemotherapy integrated treatment bag is composed of a radiotherapy pipeline and a chemotherapy pipeline, the whole integrated treatment bag is a spiral pipe body, the radiotherapy pipeline is located in an inner ring, the chemotherapy pipeline is located in an outer ring, the radiotherapy pipeline is a closed cavity, a liquid radioactive source is contained in the closed cavity, and the liquid radioactive source is located in an outer ring. The chemotherapy medicine is released from the head end of the chemotherapy pipeline, the chemotherapy medicine is injected from the tail end of the chemotherapy pipeline, and the surface of the integrated treatment bag is coated with a composite antibacterial layer. According to the integrated treatment capsule, radiopharmaceuticals and chemical drugs are placed in the inner cavity and the outer cavity respectively, synergistic treatment of radiotherapy and chemotherapy is achieved through the synchronous effect of the two channels, and long-term low-dose release of the radiopharmaceuticals and the chemotherapy drugs is achieved and toxic and side effects are reduced by adjusting the screw pitch and the thickness of the tube wall.

The invention discloses a grifola frondosa-derived exosome-like nano-vesicle as well as an extraction method and application thereof. The extraction method comprises the following steps: cutting pilei and stipes of grifola frondosa, and grinding with a proper amount of cold PBS to prepare grifola frondosa bacterial juice; the grifola frondosa juice is centrifuged at 500 g-1, 000 g, sediment is discarded, the obtained supernatant is centrifuged at 2,000 g-3,000 g, sediment is discarded, the obtained supernatant is centrifuged at 10,000 g-12,000 g, sediment is discarded, the obtained supernatant is filtered, and the pretreated grifola frondosa juice is obtained; and centrifuging the pretreated grifola frondosa juice at 30,000-100,000 g for 30 minutes to 4 hours, and resuspending by using PBS (Phosphate Buffer Solution), so as to obtain the grifola frondosa-derived exosome-like nano-vesicles. The invention develops a new thought for the mechanism of cancer inhibition, chemotherapy effect enhancement and flora regulation of the grifola frondosa, and lays a foundation for application of the grifola frondosa in development of products such as related foods, functional foods, health foods, medicines and gel-loaded medicines.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

2-diarylmethyl-4-aminotetrahydropyran derivatives are disclosed. The compounds include the following genus:or a pharmaceutically acceptable salt thereof. The compounds activate cellular PP2A, suppress oncogenic kinase signaling and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

The invention relates to the technical field of medical health informatics, and discloses a tumor patient meridian energy dynamic monitoring system and method. The system comprises a midnight-noon ebb-flow time sequence energy mapping module, a multi-modal tumor characteristic signal acquisition module, a tumor focus-meridian correlation map construction module, a chemotherapy toxic reaction prediction module and a moxibustion intervention decision module. Dynamic and accurate monitoring of the meridian energy state of a tumor patient is achieved, potential risks can be early warned 12-24 hours in advance by establishing a chemotherapy toxicity risk scoring algorithm, the life quality of the patient is remarkably improved by generating a personalized moxibustion intervention scheme, and clinical decision support is provided for traditional Chinese and western medicine combined tumor auxiliary diagnosis and treatment.

The invention relates to the field of biological medicine, and provides application of a biheterocyclic derivative in treating breast cancer and serving as an antitumor drug sensitizer. The invention discloses application of a biheterocyclic derivative in inhibiting proliferation of breast cancer cells, inhibiting formation, growth and metastasis of breast cancer tumors and enhancing chemosensitivity of the breast cancer cells and the tumors. It is found for the first time that the compound can inhibit proliferation of breast cancer cells at low concentration without affecting normal cells, and chemosensitivity of the breast cancer cells is improved. The formation and growth of breast cancer tumors can be obviously inhibited at the concentration without obvious organ toxicity, and the chemosensitivity of the breast cancer tumors is enhanced. According to the invention, the anticancer activity and the chemotherapy sensitization effect of the compound can be clarified, and a pharmaceutical basis is provided for drug development in the field of breast cancer treatment.

The invention relates to the technical field of intelligent medical prediction, in particular to an intelligent early warning method and system for adverse reactions of chemotherapy medication of tumor patients, and the method comprises the steps: inputting gene sequencing data and time sequence physiological index data of a current patient into a network model, and outputting an injury stage by the network model; the training data set of the network model comprises gene sequencing data, time sequence physiological index data and injury stages; the acquisition process of the injury stage comprises the following steps: acquiring the relative metabolic rate of the gene sequencing data to chemotherapeutics, and further determining the relative speed of in-vivo toxicity accumulation of the gene sequencing data; after time sequence physiological index data of meaningless physiological fluctuation of a historical patient is smoothed, a nerve injury change curve is obtained according to the time sequence physiological index data, whether a potential subclinical signal segment exists in the nerve injury change curve or not is recognized, and if yes, the injury stage is judged according to the potential subclinical signal segment. According to the method, individualized and accurate risk prediction can be carried out before irreversible nerve injury caused by chemotherapy occurs.

The invention discloses a design method and application of a tyrosinase (TYR) responsive drug for targeted therapy of melanoma, and belongs to the technical field of biological medicines. Based on the biological mechanism that TYR catalyzes tyrosine oxidation, a self-degradation connecting arm drug release strategy is combined, a similar 3-hydroxybenzyl alcohol structure is introduced to simulate a tyrosine substrate, specific recognition and activation of TYR on the drugs are achieved, and the problems that traditional chemotherapeutic drugs are poor in targeting property and serious in adverse reaction are hopefully solved.

The invention relates to biomedical engineering, and discloses a biochip screening method of a therapeutic agent based on intestinal brain axis regulation and application thereof. The screening method comprises the following steps: performing intestinal wall cell culture or microglial cell culture by adopting a metasurface plasmon resonance biochip of which the surface is subjected to bionic treatment to obtain an intestinal wall cell adherent chip board or a microglial cell adherent chip board; the method comprises the following steps: adding a culture medium containing a chemotherapeutic drug or lipopolysaccharide into a cell-adherent chip board for culture I, then removing the culture medium, adding a therapeutic agent to be detected for culture II to obtain a culture solution, and detecting the cell repair effect of intestinal wall cells or microglial cells in the culture solution, and screening to obtain a therapeutic agent with a repairing effect on intestinal wall cells and / or microglial cells. The screening method can be used for efficiently and accurately screening the therapeutic agent with dual effects of intestinal regulation and neuroprotection from a plurality of therapeutic agents to be detected, and can be used for dynamically monitoring and exploring the interaction condition of the therapeutic agent and cells on line in an unmarked and real-time manner.

The invention relates to a capture probe group, a kit and a sequencing library for detecting polymorphism of related genes of solid tumor chemotherapy drugs and a construction method of the sequencing library, and belongs to the technical field of high-throughput detection. The capture probe group for detecting the polymorphism of the related genes of the solid tumor chemotherapy drugs comprises nucleotide sequences as shown in SEQ ID NO.1 to SEQ ID NO.12; the related genes of the solid tumor chemotherapeutic drugs comprise MTHFR (Methylene Tetrahydrofolate Reductase), TP53, TPMT (Trimethylparaben Methyl Methyl Thiazolyl Tetrazolium), XRCC1 (XRCC1), DPYD ( According to the capture probe group, genotypes of genes related to solid tumor chemotherapy can be rapidly obtained through one-time detection, a sequencing library is constructed on the basis of the genotypes, and related information such as medication prompt, drug curative effect, toxicity and metabolic capacity corresponding to a clinical sample is obtained according to the genotypes of the sequencing library; the kit is simple and convenient to operate, consumes less time and is extremely easy to realize automatic detection.

Provided are methods and compositions for enhancing radiotherapy in various cancers by administering dopamine receptor (DRD2)‐binding phenylpiperazine derivatives such as brexpiprazole, cariprazine, pipamperone, and perospirone. In vitro studies show that combining these agents with ionizing radiation (e.g., 5 Gy) significantly reduces cancer cell survival, suppresses metastatic and stemness markers (e.g., CD44, MMP‑2, Snail, Nanog), and promotes apoptosis. Fractionated or single‐fraction radiation regimens can be paired with DRD2 antagonists to lower treatment‐resistant phenotypes, decrease the likelihood of recurrence, and potentially reduce necessary radiation dosages. The approach applies to breast, prostate, lung, pancreatic, and brain cancers, among others. Depending on tumor characteristics, additional chemotherapeutic or immunotherapeutic agents may further improve outcomes.

The invention provides a DNA (Deoxyribose Nucleic Acid) nano-structure carrier. The DNA nano-structure carrier provided by the invention has an EGFR (epidermal growth factor receptor) aptamer structure and is used for loading a connecting sequence of siRNA; moreover, after the siRNA is loaded, the DNA nano-structure carrier can further load a chemotherapeutic drug such as adriamycin, so that a DNA nano-drug based on the DNA nano-structure carrier is obtained. Through the target gene expression knock-down effect of siME3, the cytotoxicity of adriamycin and the targeting property of the EGFR aptamer structure, the DNA nano-drug provided by the invention can effectively inhibit pancreatic cancer, especially the growth of ME2 deletion type pancreatic cancer cells.

The present application relates to a kind of based on photodynamic therapy and radiotherapy and chemotherapy treatment stent and its preparation method.The present application includes stent body, stent body is mesh stent, mesh stent is provided with fixed frame, fixed frame includes the 4 support frames of cross arrangement, the cross point of 4 support frames is hinged connection.The present application is simple in structure, easy to make, convenient to use, can be made into different specifications and models, applicable to different tumor size, reduce the damage to normal tissue.

The application discloses an albumin nano-drug based on HSP90 inhibitor and a preparation method and application thereof, and belongs to the technical field of medicines.The short peptide A6 is modified to human blood albumin through a connecting chain, and the human blood albumin modified by the A6 is self-assembled with geldanamycin derivative G2111 in the presence of an organic solvent, so that the G2111 is combined to the hydrophobic region of the human blood albumin through a non-covalent bond, effective loading of the G2111 is realized, the solubility of the geldanamycin derivative is improved, the drug is targetedly released into cancer cells with high expression of CD44, the targeted accumulation of the drug in tumor tissues is enhanced, damage to other normal tissues and cells caused by off-target effects of the drug is avoided, the albumin nano-drug can be simultaneously used for chemotherapy of leukemia and solid tumors, and has important practical significance.

A traditional Chinese medicine composition for alleviating gastrointestinal toxic side effects caused by chemotherapy, the traditional Chinese medicine composition for daily administration is prepared from the following weight ratio of traditional Chinese medicine formula: Taizishen 20-30g, Fuling 10-15g, Fried Baizhu 10-15g, Zhigancao 5-10g, Jiangbanxia 5-10g, Chenpi 5-15g. The formula can effectively alleviate the gastrointestinal toxic side effects caused by chemotherapy, such as nausea, vomiting, diarrhea, poor appetite, etc.

The invention relates to the fields of pharmacology and molecular biology, and discloses an autophagy inhibitory polypeptide competitively combined with an LIR docking site of an autophagy-related protein LC3 and application of the autophagy inhibitory polypeptide. Through molecular docking simulation, through LIR docking sites of targeted LC3 protein, 794 bioactive polypeptides which can be combined are screened out. Functional result analysis shows that peptide 3 #, peptide 4 # and peptide 5 # are competitively combined with LIR docking sites of the LC3 protein, so that formation of autophagy vesicles is inhibited in a targeted manner, and proliferation and survival of autophagy-dependent pancreatic cancer cells are effectively inhibited; the strategy is combined with chemotherapeutic drugs to show a synergistic effect, and the pancreatic cancer resisting curative effect is remarkably enhanced.

The invention provides a traditional Chinese medicine preparation for treating peripheral neuropathy caused by chemotherapy, the traditional Chinese medicine preparation comprises an external preparation and an internal preparation, and discloses a preparation method and application of the traditional Chinese medicine preparation. The core pathogenesis of qi and blood stasis and yang deficiency and cold coagulation of the peripheral neuropathy caused by chemotherapy and the characteristic treatment method of tonifying qi and activating blood and warming yang and dredging collaterals are innovatively provided; the composition is rigorous and rigorous, and is clinically safe and effective.

The application discloses application of Ophisaurus apodus in preparation of a drug for reversing drug resistance of gastric cancer and belongs to the technical field of medicines. The application can reduce tumor volume and size, promote drug resistance cell apoptosis, and reverse the chemotherapeutic drug resistance of a nude mouse with gastric cancer by jointly using Ophisaurus apodus in different parts of the body and cisplatin, by down-regulating P-gp, MRP1 and Bcl-2 protein expression, and by up-regulating Bax protein expression. The effect of the tail + cisplatin group is the most significant.

The invention discloses an application of COX4I2 in preparation of a non-small cell lung cancer medicine. Specifically, the invention also discloses an application of COX4I2 in preparation of a mitochondrial iron overload preparation and an application of a COX4I2 gene inhibitor in preparation of a preparation for promoting malignant progression of tumors. According to the invention, a COX4I2-VDAC1 interaction inhibitor is screened, a COX4I2 degradation agent or cluster-competitive peptide is developed, a brand new combined chemotherapy regimen is provided for solid tumors such as NSCLC and the like, and the polypeptide has the potential of expanding to cluster metabolic disorder diseases such as neurodegenerative diseases and diabetes mellitus.

The embodiment of the application discloses a preparation method of a target temperature-sensitive drug-loaded composite microsphere based on attapulgite, which comprises the following steps: carrying out purification treatment on original attapulgite based on an aqueous solution of inorganic strong acid to obtain purified attapulgite; mixing the purified attapulgite, gypenoside, inulin and folic acid to obtain a mixture, and carrying out mixing treatment on the mixture based on deionized water to obtain a composite microsphere suspension; conveying the composite microsphere suspension into a spray dryer to carry out granulation to obtain primary drug-loaded composite microspheres; adopting a melt impregnation method to coat lauric acid on the surface and pores of the primary drug-loaded composite microspheres, and cooling the primary drug-loaded composite microspheres coated with lauric acid to room temperature to obtain the target temperature-sensitive drug-loaded composite microspheres. The application can not only realize temperature change-based on-off type control release of drugs, significantly improve the targeting and treatment accuracy of drugs, but also reduce the systemic toxic side effects of chemotherapy from the source, and realize efficient and low-toxicity synergistic treatment.

The utility model discloses a post-chemotherapy leg pain relieving device, which relates to the technical field of medical instruments and comprises an upper shell, a controller is arranged on the surface of the top of the upper shell, a telescopic rod is fixedly connected in the upper shell, a placing plate is welded at one end of the telescopic rod, a massage block is arranged on the surface of the placing plate, and the massage block is connected with the controller. The surface of the bottom of the massage block is sleeved with a buffer spring, and a movable roller is movably installed on one side of the surface of the upper shell. A controller is arranged to be matched with a telescopic rod and a placing plate, the device can be adjusted according to the thickness of the legs of a patient, the situation that the device covers too tightly and secondary injuries are caused to the legs of the patient is prevented, and the comfort degree of the device is further improved; and the device can be fixedly placed at any position by the supporting clamping plates through the sliding rails, so that the practicability of the device is further improved.

Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells including an alternating polarity (AP) magnetic field generator and one or more AP electromagnetic coil adapted to be coupled to at least a portion of a patient's body, and a controller to control the AP magnetic field generator and at least one AP electromagnetic coil and cause the field generator and coil to apply AP magnetic field having a frequency of 0.5-500 KHz and a field strength of 0.5-5 mT to the at least a portion of the patient's body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer therapy such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, an angiogenesis inhibitor drug, or tumor treatment field therapy.

Disclosed in the present invention is a combined pharmaceutical composition for treating tumors, comprising a chemotherapeutic drug and at least one compound represented by formula (I). The compound has the effect of enhancing the efficacy of the chemotherapeutic drug, thereby reducing the dose of the chemotherapeutic drug and diminishing its toxic and side effects.